NASDAQ:AKRXAkorn Stock Price, Forecast & News

Akorn's stock was trading at $0.7630 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AKRX shares have decreased by 88.2% and is now trading at $0.09. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

Akorn, Inc. (NASDAQ:AKRX) issued its earnings results on Monday, May, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.45. The business had revenue of $204.69 million for the quarter, compared to the consensus estimate of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%. View Akorn's earnings history.

2 brokerages have issued twelve-month target prices for Akorn's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Akorn's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 3,233.3% from the stock's current price. View analysts' price targets for Akorn.

News stories about AKRX stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAkorn.

Akorn saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 10,750,000 shares, an increase of 39.1% from the April 30th total of 7,730,000 shares. Based on an average daily trading volume, of 9,290,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 9.3% of the company's shares are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.32%), State Street Corp (2.36%), AQR Capital Management LLC (1.63%), Two Sigma Advisers LP (1.48%), Invesco Ltd. (1.09%) and Geode Capital Management LLC (1.08%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Two Sigma Investments LP, Geode Capital Management LLC, State Street Corp, BlackRock Inc., Spark Investment Management LLC, and GSA Capital Partners LLP. Company insiders that have sold Akorn company stock in the last year include Christopher Young, and Jonathan Kafer. View insider buying and selling activity for Akorn.

AKRX stock was purchased by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Invesco Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and Nuveen Asset Management LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $0.09.

Akorn has a market capitalization of $11.98 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

The official website for Akorn is www.akorn.com.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]